Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 10/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825404 | 1.00 | HPGD (0.44) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24341885 | 0.90 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL5102657 | 0.89 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL8518590 | 0.89 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL4715501 | 0.87 | HPGD (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL5348833 | 0.87 | HPGD (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL13769824 | 0.81 | HPGD (0.44) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL16727376 | 0.81 | HPGD (0.44) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL16727380 | 0.81 | HPGD (0.44) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24342678 | 0.81 | HPGD (0.44) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2010186-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2289893-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2112151-A2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1838710-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | HPGD 2196/4885CHRNB2 3302/4885CHRNA3 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.